炎症性肠病合并非酒精性脂肪性肝病危险因素的Meta分析

冯巩; 贺娜; 弥曼; 李雪萍; 刘曼玲; 范立萍; 牛春燕

doi:10.3969/j.issn.1001-5256.2019.04.025

炎症性肠病合并非酒精性脂肪性肝病危险因素的Meta分析

DOI: 10.3969/j.issn.1001-5256.2019.04.025

1. 西安医学院
2. 西安医学院第一附属医院
3. 厦门大学附属翔安医院消化内科

基金项目:

陕西省科技攻关计划(2016SF-327)；陕西省普通高等学校优势学科建设项目(陕教位[2014]3号)；

详细信息

中图分类号: R574;R575.5
计量
- 文章访问数: 1325
- HTML全文浏览量: 41
- PDF下载量: 296
- 被引次数: 0
出版历程
- 出版日期: 2019-04-20

Risk factors for the coexistence of inflammatory bowel disease and nonalcoholic fatty liver disease: A Meta-analysis

Xi′an Medical University

Research funding:

摘要

摘要:
目的评估糖皮质激素、TNF药物、既往炎症性肠病(IBD)相关手术史是否为IBD合并非酒精性脂肪性肝病(NAFLD)的危险因素。方法通过检索Pubmed、Embase、the Cochrane library,以及万方、知网、维普数据库(检索时间跨度为建库至2018年10月),收集关于IBD合并NAFLD的危险因素的临床研究。根据纳入与排除标准,对纳入的文献进行总结和质量评价。采用Revman5. 2软件进行数据处理,异质性数据使用随机效应模型分析,同质性数据使用固定效应模型分析。结果共纳入7篇文献,共1645例患者。Meta分析结果表明,糖皮质激素不是IBD合并NAFLD的危险因素[比值比(OR)=1. 19,95%可信区间(95%CI):0. 90～1. 57,P=0. 23];抗TNF药物也不是IBD合并NAFLD的危险因素(OR=0. 86,95%CI:0. 65～1. 13,P=0. 27); IBD相关手术史为IBD合并NAFLD的危险因素(OR=1. 50,95%CI:1. 09～2. 05,P=0. 01)。结论糖皮质激素、抗TNF药物治疗IBD不是导致NAFLD发生的危...
- 炎性肠疾病 /
- 非酒精性脂肪性肝病 /
- 危险因素 /
- Meta分析
Abstract:
Objective To investigate whether glucocorticoids, anti-tumor necrosis factor ( anti-TNF) drugs, and a past history of surgical treatment of inflammatory bowel disease ( IBD) are the risk factors for the coexistence of IBD and nonalcoholic fatty liver disease ( NAFLD) . Methods PubMed, Embase, Cochrane Library, Wanfang Data, CNKI, and VIP were searched for clinical trials of the coexistence of IBD and NAFLD published up to October 2018. The articles included were summarized and quality assessment was performed according to inclusion and exclusion criteria. RevMan 5. 2 was used for data processing; the random effects model was used for data with heterogeneity, and the fixed effect model was used for data with homogeneity. Results A total of 7 articles were included, with 1645 patients.The meta-analysis showed that glucocorticoids might not be a risk factor for the coexistence of IBD and NAFLD ( odds ratio ( OR) = 1. 19, 95% confidence interval ( CI) : 0. 90-1. 57, P = 0. 23) ; anti-TNF drugs were not a risk factor for the coexistence of IBD and NAFLD ( OR = 0. 86, 95% CI: 0. 65-1. 13, P = 0. 27) ; a past history of surgical treatment of IBD was a risk factor for the coexistence of IBD and NAFLD ( OR = 1. 50, 95% CI: 1. 09-2. 05, P = 0. 01) . Conclusion Glucocorticoids and anti-TNF drugs for the treatment of IBD may not increase the incidence rate of the coexistence of IBD and NAFLD, while surgical treatment for IBD may increase this incidence rate.
- inflammatory bowel diseases /
- nonalcoholic fatty liver disease /
- risk factors /
- Meta-analysis

HTML全文

参考文献(24)

[1]YOUNOSSI ZM, BLISSETT D, BLISSETT R, et al.The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe[J].Hepatology, 2016, 64 (5) :1577-1586.

[2]BARGIGGIA S, MACONI G, ELLI M, et al.Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease:Study of 511 subjects at a single center[J].J Clin Gastroenterol, 2003, 36 (5) :417-420.

[3] BESSISSOW T, LE NH, ROLLET K, et al.Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease[J].Inflamm Bowel Dis, 2016, 22 (8) :1937-1944.

[4]CAPPELLO M, RANDAZZO C, BRAVATI, et al.Liver function test abnormalities in patients with inflammatory bowel diseases:A hospital-based survey[J].Clin Med Insights Gastroenterol, 2014, 7:25-31.

[5]CHANDRASHEKARAN V, SETH RK, DATTAROY D, et al.HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver disease[J].Redox Biol, 2017, 13:8-19.

[6]BESSISSOW T, LE NH, ROLLET K, et al.Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease[J].Inflamm Bowel Dis, 2016, 22 (8) :1937-1944.

[7]BOSCH DE, YEH MM.Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease[J].Hum Pathol, 2017, 69:55-62.

[8]GLASSNER K, MALATY HM, ABRAHAM BP.Epidemiology and risk factors of nonalcoholic fatty liver disease among patients with inflammatory bowel disease[J].Inflamm Bowel Dis, 2017, 23 (6) :998.

[9]SAGAMI S, UENO Y, TANAKA S, et al.Significance of nonalcoholic fatty liver disease in Crohn's disease:A retrospective cohort study[J].Hepatol Res, 2017, 47 (9) :872-881.

[10]SCHRDER T, SCHMIDT KJ, OLSEN V, et al.Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment[J].Eur JGastroenterol Hepatol, 2015, 27 (6) :698-704.

[11]SOURIANARAYANANE A, GARG G, SMITH TH, et al.Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease[J].J Crohns Colitis, 2013, 7 (8) :e279-e285.

[12]SAROLI PC, RESTELLINI S, CHAO CY, et al.Screening for nonalcoholic fatty liver disease in inflammatory bowel diseases:A cohort study using transient elastography[J].Inflamm Bowel Dis, 2018.[Epub ahead of print]

[13]DOLINSKY VW, DOUGLAS DN, LEHNER R, et al.Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone[J].Biochem J, 2004, 378 (3) :967-974.

[14]D'SOUZA AM, BEAUDRY JL, SZIGIATO AA, et al.Consumption of a high-fat diet rapidly exacerbates the development of fatty liver disease that occurs with chronically elevated glucocorticoids[J].Am J Physiol Gastrointest Liver Physiol, 2012, 302 (8) :850-863.

[15]HUBEL JM, SCHMIDT SA, MASON RA, et al.Influence of plasma cortisol and other laboratory parameters on nonalcoholic fatty liver disease[J].Horm Metab Res, 2015, 47 (7) :479-484.

[16]LAPUMNUAYPOL K, KANJANAHATTAKIJ N, PISARCIK D, et al.Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease:A meta-analysis[J].Eur JGastroenterol Hepatol, 2018, 30 (8) :854-860.

[17]RUIZ AG, CASAFONT F, CRESPO J, et al.Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients:Evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis[J].Obes Surg, 2007, 17 (10) :1374-1380.

[18]BARBUIO R, MILANSKI M, BERTOLO MB, et al.Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet[J].J Endocrinol, 2007, 194 (3) :539-550.

[19]KOCA SS, BAHCECIOGLU IH, POYRAZOGLU OK, et al.The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine-and choline-deficient diet[J].Inflammation, 2008, 31 (2) :91-98.

[20]YALCIN M, AKARSU M, CELIK A, et al.A comparison of the effects of infliximab, adalimumab, and pentoxifylline on rats with non-alcoholic steatohepatitis[J].Turk J Gastroenterol, 2014, 25 (Suppl 1) :167-175.

[21]ADAMS LA, ZEIN CO, ANGULO P, et al.A pilot trial of pentoxifylline in nonalcoholic steatohepatitis[J].Am J Gastroenterol, 2004, 99 (12) :2365-2368.

[22]ANGELICO M, DELLA GP.Review article:Hepatobiliary complications associated with total parenteral nutrition[J].Aliment Pharmacol Ther, 2000, 14 (Suppl 2) :54-57.

[23]FENG G, NIU CY.Advances in the treatment of nonalcoholic fatty liver disease[J].J Clin Hepatol, 2017, 33 (12) :2433-2438. (in Chinese) 冯巩, 牛春燕.非酒精性脂肪性肝病的治疗进展[J].临床肝胆病杂志, 2017, 33 (12) :2433-2438.

[24]NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al.Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT) :Amulticentre, randomised, placebo-controlled trial[J].Lancet, 2015, 385 (9972) :956-965.

施引文献

资源附件(0)

访问统计